drug

surzebiclimab

1 story · latest Jul 17, 2026

Status: Investigational
Code: BGB-A425
Trials: 1 registered trial in coverage

Relationships

Developed by BeiGene

Timeline

BeOne Medicines registers Phase 1 bioavailability study for PRMT5 inhibitor BGB-58067

Jul 17Weekly roundup, 2 itemsalcestobart BeiGene

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.